Lilly Falls on Oral Obesity Pill as FDA Decision Looms
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Discover Eli Lilly stock insights from 4 articles covering long-term bets, timing questions, bullishness priced in, and FDA news. Learn what matters and refine portfolio today.
16 articlesEli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Eli Lilly has enjoyed rapid growth from GLP-1 drugs, but sky-high expectations invite questions about valuations. Thi...
Eli Lilly has powered higher for years, delivering eye-popping gains. But is there more room to run, or is it time to...
If you’re seeking a single, enduring reason to own Lilly stock, this article lays it out. You’ll learn how a durable ...